Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 766149 | ISIN: US03073E1055 | Ticker-Symbol: ABG
Tradegate
17.05.24
18:48 Uhr
203,95 Euro
-0,35
-0,17 %
Branche
Dienstleistungen
Aktienmarkt
S&P 500
1-Jahres-Chart
CENCORA INC Chart 1 Jahr
5-Tage-Chart
CENCORA INC 5-Tage-Chart
RealtimeGeldBriefZeit
202,70206,0013:04
203,85204,7517.05.
PR Newswire
414 Leser
Artikel bewerten:
(2)

Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement

BOSTON, Nov. 22, 2023 /PRNewswire/ -- Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribution agreement with Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation.

GoToKnow COVID-19 Antigen Rapid Test

Under the agreement, Cencora will distribute the Sapphiros GoToKnow COVID-19 Antigen Rapid Tests to pharmacies across the United States. This strategic partnership promises to enhance accessibility and convenience for those seeking reliable COVID-19 testing solutions nationwide.

In the future, Cencora will also have access to the future Sapphiros technologies including a fully disposable, low-cost multiplexed molecular diagnostics platform, additional rapid lateral flow tests for diseases beyond COVID-19 and the Satio novel blood collection patch coming in early 2024.

"This is a significant milestone for our company and further validates Sapphiros's unique and transformational technologies," said Mark Gladwell, CEO of Sapphiros. "We are honored to partner with Cencora to bring this product as well as future innovative product offerings directly to patients across the United States enabling the consumer to directly access their diagnostic results and manage their health."

About Sapphiros

Sapphiros, backed by KKR and Neoenta, is a privately held consumer diagnostics platform company. Sapphiros's portfolio of capabilities and technologies includes novel sample collection, next generation diagnostics, computational biology, and printed electronics, which help consumers access important diagnostic results globally. Knowing Now Moves Us

About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at www.investor.cencora.com

For further information: Sapphiros, press@sapphiros.com

Knowing now moves us

Photo - https://mma.prnewswire.com/media/2283196/Sapphiros.jpg
Logo - https://mma.prnewswire.com/media/1895080/4418411/Sapphiros_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/sapphiros-and-cencora-formerly-amerisourcebergen-corporation-enter-into-distribution-agreement-301995538.html

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2023 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.